Skip to main content
. 2017 Mar 7;10:35–46. doi: 10.2147/JAA.S111712

Table S2.

Concomitant use of short-acting beta 2-agonists in the ITT population

Randomized group Short-acting beta 2-agonists use
Baseline period, n (%) Double-blind period, n (%)
160 μg/day (N=119) 110 (92.4) 108 (90.8)
320 μg/day (N=122) 105 (86.1) 103 (84.4)
640 μg/day (N=126) 108 (85.7) 108 (85.7)

Abbreviation: ITT, intention-to-treat.